Role of Sirtuins in Diabetes and Age-Related Processes

The practice of intermittent fasting continues to grow as a widely practiced diet trend due to its feasibility and reported high success rate. By practicing intermittent fasting, levels of sirtuin proteins (SIRTs), also known as the longevity protein, rise in the body and bring numerous health benefits. Currently, seven SIRTs have been described in humans in different locations of the cell with a wide variety of corresponding functions including gene transcription, DNA repair, and protection against oxidative damage. SIRT activators, such as resveratrol found in red wine, are also commonly consumed to amplify the health benefits associated with protection against diabetes and age-related disease processes. The purpose of this review is to explore the interaction of intermittent fasting on SIRT levels and how the increase in these proteins impacts age-related disease processes. The understanding of SIRTs is continuously evolving as more interactions and SIRT-specific activators are being revealed. New discoveries are crucial for forming potential therapeutics that delay many common diseases and promote healthy living.

[1]  C. Silaghi,et al.  Sirtuin 3 (SIRT3) Pathways in Age-Related Cardiovascular and Neurodegenerative Diseases , 2021, Biomedicines.

[2]  Hui Huang,et al.  Deletion of soluble epoxide hydrolase suppressed chronic kidney disease-related vascular calcification by restoring Sirtuin 3 expression , 2021, Cell Death & Disease.

[3]  Jordan D. Miller,et al.  Sirtuin 6 Protects Against Oxidative Stress and Vascular Dysfunction in Mice , 2021, Frontiers in Physiology.

[4]  P. Mikołajczak,et al.  Sirtuin 1 as the mechanism of action of agents used in the diabetes mellitus pharmacotherapy. , 2021, European journal of pharmacology.

[5]  Hui Yang,et al.  Hippocampal insulin resistance and the Sirtuin 1 signaling pathway in diabetes-induced cognitive dysfunction , 2021, Neural regeneration research.

[6]  Nitish Kumar,et al.  Dysregulation of SIRT-1 Signaling in Multiple Sclerosis and Neuroimmune Disorders: A Systematic Review on SIRTUIN Activators as Potential Immunomodulators and Influences on other Dysfunctions. , 2021, Endocrine, metabolic & immune disorders drug targets.

[7]  J. Auwerx,et al.  Pharmacological and Genetic Perturbation Establish SIRT5 as a Promising Target in Breast Cancer , 2020, Oncogene.

[8]  Shudong Wang,et al.  Epigenetic Regulation Associated With Sirtuin 1 in Complications of Diabetes Mellitus , 2021, Frontiers in Endocrinology.

[9]  Shih-Jen Chen,et al.  Changes in the Systemic Expression of Sirtuin-1 and Oxidative Stress after Intravitreal Anti-Vascular Endothelial Growth Factor in Patients with Retinal Vein Occlusion , 2020, Biomolecules.

[10]  J. Kim,et al.  The Role of Sirtuins in Kidney Diseases , 2020, International journal of molecular sciences.

[11]  S. Makpol,et al.  Antioxidant Modulation of mTOR and Sirtuin Pathways in Age-Related Neurodegenerative Diseases , 2020, Molecular Neurobiology.

[12]  Fengzhou Xu,et al.  Association of sirtuin-1 and vascular endothelial growth factor expression with tumor progression and poor prognosis in liposarcoma , 2020, The Journal of international medical research.

[13]  G. Remuzzi,et al.  Manipulating Sirtuin 3 pathway ameliorates renal damage in experimental diabetes , 2020, Scientific Reports.

[14]  V. Singh,et al.  Role of Silent Information Regulator 1 (SIRT1) in Regulating Oxidative Stress and Inflammation , 2020, Inflammation.

[15]  A. Mai,et al.  Sirtuin modulators: where are we now? A review of patents from 2015 to 2019 , 2020, Expert opinion on therapeutic patents.

[16]  C. Zheng,et al.  Sirtuin-1 and Its Relevance in Vascular Calcification , 2020, International journal of molecular sciences.

[17]  Yuchen Ge,et al.  SIRT1 and aging related signaling pathways , 2020, Mechanisms of Ageing and Development.

[18]  M. Packer.  Interplay of adenosine monophosphate‐activated protein kinase/sirtuin‐1 activation and sodium influx inhibition mediates the renal benefits of sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes: A novel conceptual framework , 2020, Diabetes, obesity & metabolism.

[19]  F. Reis,et al.  The yin and yang faces of the mitochondrial deacetylase sirtuin 3 in age-related disorders , 2019, Ageing Research Reviews.

[20]  R. de Cabo,et al.  Effects of Intermittent Fasting on Health, Aging, and Disease. , 2019, The New England journal of medicine.

[21]  Min-xia Zhu,et al.  Exploring the role of orexin B-sirtuin 1-HIF-1α in diabetes-mellitus induced vascular endothelial dysfunction and associated myocardial injury in rats. , 2019, Life sciences.

[22]  L. Cai,et al.  Role of sirtuin-1 in diabetic nephropathy , 2019, Journal of Molecular Medicine.

[23]  Q. Zeng,et al.  A SIRT1 agonist reduces cognitive decline in type 2 diabetic rats through antioxidative and anti-inflammatory mechanisms , 2018, Molecular medicine reports.

[24]  Matheus Roriz‐Cruz,et al.  Sirtuin 1 and Alzheimer's disease: An up-to-date review , 2018, Neuropeptides.

[25]  Jing Luo,et al.  Role of Sirtuin 1 in the pathogenesis of ocular disease (Review). , 2018, International journal of molecular medicine.

[26]  Jin Zhou,et al.  Resveratrol attenuates type 2 diabetes mellitus by mediating mitochondrial biogenesis and lipid metabolism via Sirtuin type 1. , 2017, Experimental and therapeutic medicine.

[27]  E. Bae.  Sirtuin 6, a possible therapeutic target for type 2 diabetes , 2017, Archives of Pharmacal Research.

[28]  M. Mattson,et al.  Impact of intermittent fasting on health and disease processes , 2017, Ageing Research Reviews.

[29]  D. Lombard,et al.  Sirtuin 6 Builds a Wall Against Inflammation, Trumping Diabetes , 2017, Diabetes.

[30]  P. Damonte,et al.  Pharmacological Sirt6 inhibition improves glucose tolerance in a type 2 diabetes mouse model , 2017, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[31]  De-Pei Liu,et al.  Age-Associated Sirtuin 1 Reduction in Vascular Smooth Muscle Links Vascular Senescence and Inflammation to Abdominal Aortic Aneurysm. , 2016, Circulation research.

[32]  R. Weisbrod,et al.  Vascular Smooth Muscle Sirtuin-1 Protects Against Diet-Induced Aortic Stiffness , 2016, Hypertension.

[33]  K. Turkmen,et al.  The Emerging Role of Sirtuin 1 in Cellular Metabolism, Diabetes Mellitus, Diabetic Kidney Disease and Hypertension. , 2015, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[34]  Ke Yang,et al.  Sirtuin 1 participates in the process of age-related retinal degeneration. , 2015, Biochemical and biophysical research communications.

[35]  Xianzhong Meng,et al.  Activation of sirtuin 1/3 improves vascular hyporeactivity in severe hemorrhagic shock by alleviation of mitochondrial damage , 2015, Oncotarget.

[36]  R. Thandavarayan,et al.  Sirtuin‐6 deficiency exacerbates diabetes‐induced impairment of wound healing , 2015, Experimental dermatology.

[37]  H. El-Mesallamy,et al.  Fenofibrate reduces inflammation in obese patients with or without type 2 diabetes mellitus via sirtuin 1/fetuin A axis. , 2015, Diabetes research and clinical practice.

[38]  Yanhang Zhang,et al.  Vascular Smooth Muscle Sirtuin-1 Protects Against Aortic Dissection During Angiotensin II–Induced Hypertension , 2015, Journal of the American Heart Association.

[39]  K. Şahin,et al.  Protective effects of resveratrol against streptozotocin-induced diabetes in rats by modulation of visfatin/sirtuin-1 pathway and glucose transporters , 2015, International journal of food sciences and nutrition.

[40]  A. Mai,et al.  Sirtuin modulators: an updated patent review (2012 – 2014) , 2015, Expert opinion on therapeutic patents.

[41]  A. Kucuk,et al.  Sirtuins as novel players in the pathogenesis of diabetes mellitus. , 2014, World journal of diabetes.

[42]  J. He,et al.  In vivo RNA interference models of inducible and reversible Sirt1 knockdown in kidney cells. , 2014, The American journal of pathology.

[43]  Lanfang Li,et al.  Apelin gene therapy increases myocardial vascular density and ameliorates diabetic cardiomyopathy via upregulation of sirtuin 3. , 2014, American journal of physiology. Heart and circulatory physiology.

[44]  Won-Young Lee,et al.  Nicotinamide improves glucose metabolism and affects the hepatic NAD-sirtuin pathway in a rodent model of obesity and type 2 diabetes. , 2014, The Journal of nutritional biochemistry.

[45]  J. Welch,et al.  Sirtuin 6: a review of biological effects and potential therapeutic properties. , 2013, Molecular bioSystems.

[46]  P. Puigserver,et al.  The sirtuin family's role in aging and age-associated pathologies. , 2013, The Journal of clinical investigation.

[47]  M. Bennett,et al.  Vascular Smooth Muscle Cell Sirtuin 1 Protects Against DNA Damage and Inhibits Atherosclerosis , 2013, Circulation.

[48]  X. Dong,et al.  Sirtuin biology and relevance to diabetes treatment. , 2012, Diabetes management.

[49]  R. de Cabo,et al.  A patent review of sirtuin activators: an update , 2012, Expert opinion on therapeutic patents.

[50]  J. Auwerx,et al.  Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. , 2011, Cell metabolism.

[51]  Qing Xu,et al.  Myeloid Deletion of SIRT1 Induces Inflammatory Signaling in Response to Environmental Stress , 2010, Molecular and Cellular Biology.

[52]  C. Leeuwenburgh,et al.  Resveratrol and novel potent activators of SIRT1: effects on aging and age-related diseases. , 2008, Nutrition reviews.

[53]  M. Reeves,et al.  Effect of intensive dietetic interventions on weight and glycaemic control in overweight men with Type II diabetes: a randomised trial , 2003, International Journal of Obesity.